Craft

Cipla

Stock Price

₹916.3

2023-05-19

Market Capitalization

₹739.6 B

2023-05-19

Revenue

₹224.7 B

FY, 2023

Cipla Summary

Company summary

Overview
Cipla is a global pharmaceutical company, which offers active pharmaceutical ingredients and formulations in various therapeutic areas, such as women’s health, cardiovascular, children’s health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The Company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals.
Type
Public
Status
Active
Founded
1935
HQ
Mumbai, IN | view all locations
Website
http://www.cipla.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key people

  • Umang Vohra

    Umang Vohra, Managing Director & Global Chief Executive Officer

  • Philippe Malecki

    Philippe Malecki, Regional Head APAC

  • Anchal Sultania

    Anchal Sultania, Business Head - Europe and Russia CIS

  • Anand Agarwal

    Anand Agarwal, Regional Head - MEPAC

LocationsView all

13 locations detected

  • Mumbai, MH HQ

    India

    1, Peninsula Spenta, Mathuradas Mill Compound, Senapati Bapat Marg, Lower Parel

  • Central Islip, NY

    United States

    550 S Research Pl

  • South Melbourne, VIC

    Australia

    Level 1/132 Albert Rd

  • Mumbai, MH

    India

    2nd Floor, Bldg, 5, LBS Rd, Suryanagar No. 2, HMPL Surya Nagar, Vikhroli West

  • Nairobi, Nairobi County

    Kenya

    Chiromo Road Purshottam Place

  • Cape Town, WC

    South Africa

    Mispel Street, Bellville

and 7 others

Cipla Financials

Summary financials

Revenue (FY, 2023)
₹224.7B
Gross profit (FY, 2023)
₹149.8B
Net income (FY, 2023)
₹28.4B
Cash (Q2, 2023)
₹18.3B
EBIT (FY, 2023)
₹41.5B
Enterprise value
$731.9B

Blogs

Footer menu